Sat, Sep 20, 2014, 8:03 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

  • Dooper55 Dooper55 Apr 10, 2012 8:15 AM Flag

    2nd OMS302 Phase 3 clinical trial underway

    Omeros Announces Enrollment In Second Phase 3 Clinical Trial Evaluating OMS302

    –Data from Trial Expected in Second Half of 2012–


    SEATTLE, April 10, 2012 /PRNewswire/ – Omeros Corporation (OMER) today announced that patient enrollment has begun in the Company’s second Phase 3 clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery. OMS302, one of Omeros’ proprietary PharmacoSurgery™ products, is added to standard irrigation solution used during ILR procedures to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain. In the first Phase 3 clinical trial of OMS302, the drug product demonstrated statistically significant superiority over placebo in maintenance of intraoperative mydriasis (p<0.00001) and reduction of postoperative pain (p<0.00001).

    Like the initial Phase 3 clinical trial, this second Phase 3 trial will enroll approximately 400 patients undergoing cataract surgery or refractive lens exchange. Randomized, double-blind, placebo-controlled and multicenter, this trial will evaluate the same efficacy and safety measures as the earlier successful Phase 2b and Phase 3 clinical trials. Data are expected in the second half of 2012.

    “Given the strength and consistency of the data from the earlier Phase 2b and Phase 3 clinical trials of OMS302, we look forward to reporting results from our second Phase 3 trial later this year,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “Our previous OMS302 trials enrolled rapidly, and we expect a similar enrollment rate in this trial. We have begun preparing our NDA and, assuming positive data, are targeting a submission date in the first part of 2013.”

 
OMER
13.20-0.40(-2.94%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.